A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms THOR
- Sponsors Janssen Research & Development; Janssen-Cilag
- 14 Nov 2018 Planned End Date changed from 30 Apr 2022 to 1 Feb 2021.
- 01 May 2018 Status changed from not yet recruiting to recruiting.
- 11 Mar 2018 Planned number of patients changed from 630 to 631.